Regenxbio INC 10-Q quarterly reports

REGENXBIO Inc. announced a significant increase in revenue driven by a $100 million milestone payment from AbbVie, alongside positive clinical trial updates for RGX-202 and RGX-121, and substantial capital raised.

REGENXBIO Inc. files its Q1 2026 10-Q, detailing significant revenue decline, increased R&D expenses, and ongoing clinical trial progress.

REGENXBIO Inc. reported a reduced net loss for the nine months ended September 30, 2025, driven by increased collaboration revenue, while advancing multiple gene therapy programs including ABBV-RGX-314, RGX-202, and RGX-121.

REGENXBIO Inc. reported increased revenue driven by a new collaboration, secured a significant royalty bond, and advanced its gene therapy pipeline despite widening net losses.

REGENXBIO's Q1 2025 revenue surged due to a collaboration with Nippon Shinyaku, offsetting increased operating expenses and resulting in a net income of $6.1 million.

REGENXBIO's Q3 2024 report details financial results, clinical trial progress, and strategic updates, including a focus on key gene therapy programs.

REGENXBIO's Q2 2024 report highlights progress in clinical trials, financial updates, and a leadership transition.

REGENXBIO's first quarter 2024 results show a decrease in revenue compared to the same period last year, alongside a reduction in operating expenses and a successful capital raise.